Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood

American Journal of Health-System Pharmacy

Volumn 55, Issue 24 SUPPL., 1998, Pages

  Driver, Paul S ^a  

^a Portneuf Medical Center   (United States)

Author keywords

Anemia; Blood; Costs; Dialysis; Dosage; Epoetin alfa; Hematopoietic agents; Iron dextran; Iron preparations; Pharmacoeconomics; Protocols

Indexed keywords

FERRITIN; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG UTILIZATION; FEMALE; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032535357     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.suppl_4.s12     Document Type: Conference Paper

References (22)

1. Sunder-Plassmann G, Horl WH. Erythropoietin and iron. Clin Nephrol. 1997; 47(3):141-57.
2. Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis. 1997; 29:319-33.
3. Watson A. Iron management during treatment with recombinant human erythropoietin in chronic renal failure. J Clin Pharmacol. 1993; 33:1134-8.
4. Sunder-Plassmann G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995; 10: 2070-6.
5. Bergmann M, Grutzmacher P, Heuser J et al. Iron metabolism under rEPO therapy in patients on maintenance hemodialysis. Int J Artif Organs. 1990; 13:109-12.
6. York S. Current perspectives: iron management during therapy with recombinant human erythropoietin. ANNA J. 1993; 20:645-51.
7. Sunder-Plassmann G, Horl WH. Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Saf. 1997; 17:241-50.
8. Senger JM, Weiss RJ. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. Am Nephrol Nurses Assoc J. 1996; 23:319-25.
9. Fishbane S, Ungureanu V, Maesaka JK et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996; 28:529-34.
10. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995; 26:41-6.
11. Park L, Uhthoff T, Tierney M et al. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients. Am J Kidney Dis. 1998; 31:835-40.
12. Taylor JE, Peat N, Porter C et al. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1996; 11:1079-83.
13. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research. New York: Wiley; 1982.
14. Eschbach J, DeOreo P. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis. 1997; 30(suppl 3):s192-237.
15. Health Care Financing Administration. Medicare coverage of kidney dialysis and kidney transplant services. http://www. medicare.gov (accessed 1998 Jun 19).
16. Your medicare handbook 1997. www.medicare.gov (accessed 1998 Jun 19).
17. Ifudu O, Macey LJ, Friedman EA. Resurgence of blood transfusion therapy in erythropoietin treated hemodialysis patients. ASAIO J. 1995; 41:M426-30.
18. Program memorandum, intermediaries/carriers. HCFA publication 60AB. Rev. AB-97-2. http://www.hcfa.gov (accessed 1998 May 5).
19. Moran LJ, Carey P, Johnson CA. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease. Am J Hosp Pharm. 1992; 49:1451-4.
20. Nissenson AR. Achieving target hematocrit in dialysis patients: new concepts in iron management. Am J Kidney Dis. 1997; 30:907-11.
21. Sepandj F, Jindal K, West M et al. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant. 1996; 11:319-22.
22. McNamee P, van Doorslaer E, Segaar R. Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Int J Technol Assess Health Care. 1993; 9:490-504.